Prévisions du marché européen de l\'épilepsie jusqu\'en 2030 - Analyse régionale - par type (épilepsie myoclonique progressive, épilepsie réflexe, épilepsie généralisée et autres), voie d\'administration (orale, parentérale et autres), type de traitement (médicaments de première génération, médicaments de deuxième génération et médicaments de troisième génération), groupe d\'âge (adultes et enfants) et canal de distribution (pharmacies hospitalières, pharmacies de détail et autres)
L\'augmentation des investissements dans le développement des thérapies contre l\'épilepsie stimule le marché européen de l\'épilepsie
Le secteur de la santé se transforme avec des développements technologiques et des innovations rapides, améliorant les services de santé et la qualité des soins. Le marché de l\'épilepsie est caractérisé par la présence de plusieurs petites et grandes entreprises et organisations mettant en œuvre diverses stratégies de croissance. La disponibilité du financement permet aux entreprises et aux organisations d\'augmenter les niveaux de production, de se développer sur de nouveaux marchés, d\'investir dans des technologies nouvelles/améliorées et d\'allouer davantage de ressources à la R&D. Quelques-uns des investissements notables sur le marché de l\'épilepsie, contribuant aux progrès du marché, ont été mentionnés ci-dessous.
• En mars 2023, le gouvernement suédois a décidé de confier à Vinnova, l\'agence suédoise de l\'innovation, un total de 7,7 millions de dollars (80 millions de SEK) pour établir un pôle d\'innovation national pour la commercialisation, le développement des compétences et le renforcement des capacités de production pour les thérapies cellulaires et d\'autres traitements avancés tels que la thérapie génique.
• En novembre 2022, des scientifiques de l\'université Aston au Royaume-Uni, travaillant sur un projet visant à développer de nouveaux traitements médicamenteux pour prévenir l\'apparition de l\'épilepsie infantile, ont reçu 2,4 millions de dollars (2 millions de livres sterling) pour découvrir le mécanisme de la maladie dans le cerveau et les moyens de prévention de l\'épilepsie. Ce projet de trois ans financé par le Medical Research Council est une collaboration menée par des chercheurs du College of Health and Life Sciences de l\'université Aston, en collaboration avec l\'université de Bristol et Jazz Pharmaceuticals.
• En juillet 2022, Cerebral Therapeutics a obtenu 40 millions de dollars dans le cadre du financement de série C pour préparer son traitement de l\'épilepsie par perfusion implantée pour le développement de phase 3. Le tour de financement a été mené par Lynx1 Capital Management parmi d\'autres investisseurs, dont RA Capital Management et Perceptive Advisors. Cerebral Therapeutics a l\'intention de délivrer les niveaux spécifiés de valproate au système nerveux central sans provoquer de prise de poids, ce qui a été observé chez les sujets des études de formulation orale.
• En novembre 2021, Neurava, une startup située dans l\'Indiana, a reçu plus de 0,65 million de dollars US de financement d\'amorçage dirigé par Elevate Ventures avec la participation de Purdue Foundry, UCB Biopharma, First Leaf Capital, iO Life Ventures et des investisseurs providentiels. L\'entreprise travaille sur le développement d\'un appareil portable pour surveiller et alerter les utilisateurs du risque imminent de mort subite et inattendue causée par l\'épilepsie.
• En juin 2021, Neurona Therapeutics Inc., une société biothérapeutique, a finalisé avec succès un financement de 41,5 millions de dollars américains pour faire progresser le pipeline de thérapies cellulaires prêtes à l\'emploi en propriété exclusive de la société pour diverses indications, notamment NRTX-1001 (une étude clinique de phase 1/2a), une thérapie cellulaire neuronale inhibitrice pour le traitement de l\'épilepsie focale chronique.
Par conséquent, l\'augmentation des investissements dans le développement de traitements avancés propulse la croissance du marché de l\'épilepsie.
Aperçu du marché européen de l\'épilepsie
Le marché européen de l\'épilepsie est segmenté en Allemagne, au Royaume-Uni, en France, en Italie, en Espagne et dans le reste de l\'Europe. La région détient une part de marché importante sur le marché de l\'épilepsie. Le marché européen de l\'épilepsie devrait connaître une croissance significative au cours de la période de prévision en raison de facteurs tels que la croissance significative de la population âgée, l\'approbation de nouveaux médicaments par les autorités réglementaires, l\'augmentation du financement des gouvernements pour améliorer et développer des médicaments et des traitements efficaces contre les crises dans la région.
Chiffre d\'affaires et prévisions du marché européen de l\'épilepsie jusqu\'en 2030 (en millions de dollars américains)
Segmentation du marché européen de l\'épilepsie
Le marché européen de l\'épilepsie est classé en type, voie d\'administration, type de traitement, tranche d\'âge, canal de distribution et pays.
En fonction du type, le marché européen de l\'épilepsie est classé en épilepsie myoclonique progressive, épilepsie réflexe, épilepsie généralisée et autres. Le segment de l\'épilepsie généralisée détenait la plus grande part de marché en 2022.
En termes de voie d\'administration, le marché européen de l\'épilepsie est classé en voie orale, parentérale et autres. Français Le segment oral détenait la plus grande part de marché en 2022.
Par type de traitement, le marché européen de l\'épilepsie est segmenté en médicaments de première génération, médicaments de deuxième génération et médicaments de troisième génération. Le segment des médicaments de troisième génération détenait la plus grande part de marché en 2022.
En fonction du groupe d\'âge, le marché européen de l\'épilepsie est divisé en adultes et enfants. Le segment des adultes détenait une part de marché plus importante en 2022.
En termes de canal de distribution, le marché européen de l\'épilepsie est classé en pharmacies hospitalières, pharmacies de détail et autres. Le segment des pharmacies hospitalières détenait la plus grande part de marché en 2022.
Par pays, le marché européen de l\'épilepsie est segmenté en Royaume-Uni, Allemagne, France, Italie, Espagne et reste de l\'Europe. Le Royaume-Uni a dominé la part de marché de l\'épilepsie en Europe en 2022.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc et H. Lundbeck AS sont quelques-unes des principales sociétés opérant sur le marché européen de l\'épilepsie.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Europe Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Europe Analysis
6.1 Europe: Epilepsy Market
7. Europe Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Europe Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Europe Epilepsy Market - Country Analysis
12.1 Europe: Epilepsy Market Overview
12.1.1 Europe: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 United Kingdom: Epilepsy Market Overview
12.1.1.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
12.1.1.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Germany: Epilepsy Market Overview
12.1.1.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Germany: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Germany: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 France: Epilepsy Market Overview
12.1.1.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 France: Epilepsy Market Breakdown, by Type
12.1.1.6.2 France: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 France: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 France: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Spain: Epilepsy Market Overview
12.1.1.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Spain: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Spain: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.9 Italy: Epilepsy Market Overview
12.1.1.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.10.1 Italy: Epilepsy Market Breakdown, by Type
12.1.1.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
12.1.1.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
12.1.1.10.4 Italy: Epilepsy Market Breakdown, by Age Group
12.1.1.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.11 Rest of Europe: Epilepsy Market Overview
12.1.1.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
12.1.1.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
12.1.1.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
12.1.1.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
12.1.1.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 CombiGene AB
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 LivaNova Plc
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Medtronic Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 GSK Plc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 H. Lundbeck AS
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
?
List of Tables
Table 1. Europe Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
Table 11. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 32. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 33. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 34. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 35. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 36. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 37. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 38. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 39. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 40. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 41. Recent Organic Growth Strategies in Epilepsy Market
Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. Europe Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in Epilepsy Market
?
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- CombiGene AB
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.